Study of WGI-0301 for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, WGI-0301, for people with advanced hepatocellular carcinoma (HCC, a type of liver cancer) that has progressed after standard treatments. It aims to see if WGI-0301 can help control the cancer when other options have stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced liver cancer (HCC) that cannot be surgically removed or treated with local therapies.
- Your cancer has gotten worse or you could not tolerate at least one standard treatment (such as immunotherapy or a targeted drug).
- You have a tumor that can be measured on scans and has not been treated with local therapies like chemoembolization or ablation (unless it grew in that area).
- Your liver function is good enough (Child-Pugh class A or B with score 7 or less) and your blood work shows adequate organ function.
- You are willing to provide a tumor tissue sample if available, and agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs—WGI-0301 and lenvatinib—to treat advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed. It's designed for patients whose cancer has progressed despite prior treatments.
This trial tests a new drug called WGI-0301 combined with the immunotherapy nivolumab for people with advanced liver cancer (HCC) or certain types of kidney cancer (RCC). The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a new type of cell therapy called C-CAR031, which is designed to target and attack liver cancer cells that have a protein called GPC3. It is for people with advanced liver cancer who have already tried other treatments and are looking for a new option.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Hear when a new Advanced Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.